Investment

Features

Fees Safety

Academy

Pluang+

Home/News Feed/JNJ raises 2026 outlook after 6.6% Q2 sales growth led by DARZALEX and TREMFYA

JNJ

$270.24

+$2.87 +1.07%

JNJ raises 2026 outlook after 6.6% Q2 sales growth led by DARZALEX and TREMFYA

Analyst Insights

22 Aug 2026

Seeking Alpha

View Source

Bullish

Johnson & Johnson (JNJ) reported a 6.6% revenue increase to $25.3 billion in Q2 2026, driven by strong sales of key drugs DARZALEX and TREMFYA. The company raised its full-year 2026 guidance, supported by pipeline advancements including CAPLYTA's label expansion for schizophrenia relapse prevention and IMAAVY's potential first-mover status in wAIHA. Risks remain around sustaining high sales growth and regulatory approvals for pipeline assets. This positive momentum underpins JNJ's maintained 'Buy' rating by analysts.

More News (JNJ)

Dividend Kings like JNJ, PG, KO, PEP, and MCD keep raising payouts amid market volatility in August 2026.

In August 2026, several blue-chip Dividend Kings and Aristocrats, including Johnson & Johnson, Procter & Gamble, Coca-Cola, PepsiCo, and McDonald's, continued their long-standing tradition of raising dividends. These companies showed strong cash flow...

Market News

Neutral

4 days ago